Home / SLDB : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does SLDB make money? Does SLDB have pricing power? What's the Earnings Whisper? Will SLDB profit more as the business scales? What is SLDB's management track record? Is SLDB's current price justified?

Solid Biosciences Inc.

$8.7 +$3.25 (+59.63%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$9.07

Day Range

$8.65$9.37

Year Range

$3.79$11.45

Market Cap

856.51M

AVG Volume

1.45M

Trailing/Forward PE

-4.55/-

PEG ratio

5.8

Dividend Yield

Next Earnings Date

2026-11-02

Primary Exchange

NASDAQ

Revenue (USD)

SLDB Revenue (USD) by year
Period	Revenue (USD)
2025	0
2024	0
2023	0
2022	8.09M
2021	13.62M
2020	0
2019	0
2018	0
2017	0

Net Income (USD)

SLDB Net Income (USD) by year
Period	Net Income (USD)
2025	-174.32M
2024	-124.7M
2023	-96.02M
2022	-85.98M
2021	-72.19M
2020	-88.29M
2019	-117.22M
2018	-74.8M
2017	-52.12M

Operating Income (USD)

SLDB Operating Income (USD) by year
Period	Operating Income (USD)
2025	-179.21M
2024	-129.73M
2023	-104.25M
2022	-106.45M
2021	-72.25M
2020	-88.41M
2019	-119.32M
2018	-75.69M
2017	-54.86M

EBITDA (USD)

SLDB EBITDA (USD) by year
Period	EBITDA (USD)
2025	-172.56M
2024	-121.9M
2023	-93.1M
2022	-96.1M
2021	-69.2M
2020	-82.54M
2019	-116.49M
2018	-74.12M
2017	-54.41M

Cash Flows (USD)

SLDB Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-157.44M
2024	-100.67M
2023	-95.69M
2022	-100.99M
2021	-79.05M
2020	-57.5M
2019	-97.1M
2018	-77.97M
2017	-45.5M

EPS (USD)

SLDB EPS (USD) by year
Period	EPS (USD)
2025	-2.02
2024	-2.84
2023	-4.54
2022	-11.27
2021	-10.24
2020	-25.39
2019	-44.14
2018	-33.61
2017	-30.66

Expenses (USD)

SLDB Expenses (USD) by year
Period	Expenses (USD)
2025	180.36M
2024	130.38M
2023	105.83M
2022	110.38M
2021	87.16M
2020	87.36M
2019	123.7M
2018	83.46M
2017	57.13M

Cash & Debt (USD)

SLDB Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	187.85M
2024	148.92M
2023	123.64M
2022	213.72M
2021	207.78M
2020	154.74M
2019	83.52M
2018	122.46M
2017	69.09M

Debt ratios

SLDB Debt ratios by year
Period	Debt ratios
2025	0.34
2024	0.33
2023	0.29
2022	0.51
2021	0.6
2020	0.46

Margins

SLDB Margins by year
Period	Margins
2022	100%
2021	100%

Return on Capital

SLDB Return on Capital by year
Period	Return on Capital
2025	-96.84%
2024	-90.86%
2023	-75.91%
2022	-40.62%
2021	-34.67%
2020	-66.84%
2019	-146.44%
2018	-59.75%
2017	87.95%

Shares Outstanding

SLDB Shares Outstanding by year
Period	Shares Outstanding
2025	94.73M
2024	53.58M
2023	29.02M
2022	8.02M
2021	7.36M
2020	4.71M
2019	3.2M
2018	2.31M
2017	1.28M

Book Value Per Share (USD)

SLDB Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	1.9
2024	2.56
2023	4.36
2022	26.38
2021	28.3
2020	28.06
2019	25.03
2018	54.19
2017	-46.22

Total Assets (USD)

SLDB Total Assets (USD) by year
Period	Total Assets (USD)
2025	232.54M
2024	188.66M
2023	164.94M
2022	260.25M
2021	232.38M
2020	171.17M
2019	103.47M
2018	139.6M
2017	76.19M

Employee Count

SLDB Employee Count by year
Period	Employee Count
2025	121
2024	100
2023	88
2022	87
2021	104
2020	70
2019	121
2018	111
2017	60

Free Cash Flow Yield

SLDB Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-15.02%
Sep 26	-12.75%
Aug 26	-13.38%
Aug 26	-14.05%
Aug 26	-14.21%
Aug 26	-15.58%
Jul 26	-19.53%
Jul 26	-20.1%
Jul 26	-18.05%
Jul 26	-15.11%
Jul 26	-14.52%
Jun 26	-16.94%
Jun 26	-18.9%
Jun 26	-22.05%
Jun 26	-23.49%
May 26	-21.45%
May 26	-23.78%
May 26	-22.75%
May 26	-22.86%
May 26	-23.31%
Apr 26	-20.98%
Apr 26	-19.26%
Apr 26	-20.72%
Apr 26	-22.19%
Mar 26	-23.38%
Mar 26	-23.64%
Mar 26	-19.29%
Mar 26	-20.9%
Feb 26	-22.71%
Feb 26	-24.7%
Feb 26	-22.79%
Feb 26	-21.63%
Jan 26	-21.83%
Jan 26	-21.37%
Jan 26	-25.79%
Jan 26	-26.66%
Jan 26	-25.88%
Dec 25	-24.15%
Dec 25	-23.75%
Dec 25	-24.03%
Dec 25	-24.44%
Nov 25	-25.98%
Nov 25	-30.01%
Nov 25	-33.27%
Nov 25	-34.74%
Oct 25	-24.31%
Oct 25	-23.31%
Oct 25	-22.28%
Oct 25	-21.98%
Oct 25	-22.21%
Sep 25	-21.3%
Sep 25	-25.59%
Sep 25	-24.31%
Sep 25	-23.82%
Aug 25	-23.91%
Aug 25	-22.09%
Aug 25	-21.44%
Aug 25	-25.71%
Aug 25	-23.68%
Jul 25	-23.11%
Jul 25	-25.31%
Jul 25	-30.75%
Jul 25	-32.16%
Jun 25	-34.27%
Jun 25	-33.77%
Jun 25	-35.86%
Jun 25	-35.63%
May 25	-50.39%
May 25	-57.56%
May 25	-58.39%
May 25	-68.07%
May 25	-43.59%
Apr 25	-56.93%
Apr 25	-73.68%
Apr 25	-69.59%
Apr 25	-60.22%
Mar 25	-43.49%
Mar 25	-40.84%
Mar 25	-36.91%
Mar 25	-34.66%
Feb 25	-39.6%
Feb 25	-38.29%
Feb 25	-54.92%
Feb 25	-76.85%
Jan 25	-69.6%
Jan 25	-68.95%
Jan 25	-67.69%
Jan 25	-60.15%
Jan 25	-53.46%
Dec 24	-52.2%
Dec 24	-53.21%
Dec 24	-45.08%
Dec 24	-43.83%
Nov 24	-38.83%
Nov 24	-40.91%
Nov 24	-45.64%
Nov 24	-37.71%
Nov 24	-36.66%
Oct 24	-36.92%
Oct 24	-31.94%

Price to Sales

SLDB Price to Sales by year
Period	Price to Sales
Aug 23	12.05
Aug 23	11.89
Jul 23	13.89
Jul 23	15.03
Jul 23	15.57
Jul 23	16.72
Jun 23	16.62
Jun 23	17.41
Jun 23	22.24
Jun 23	20.11
Jun 23	19.95
May 23	19.54
May 23	19.03
May 23	20.05
May 23	5.3
Apr 23	4.84
Apr 23	4.82
Apr 23	5.03
Apr 23	4.74
Mar 23	4.7
Mar 23	3.65
Mar 23	2.75
Mar 23	3.29
Mar 23	3.55
Feb 23	4.02
Feb 23	4.64
Feb 23	4.66
Feb 23	5.12
Jan 23	5.12
Jan 23	4.91
Jan 23	4.52
Jan 23	3.92
Dec 22	3.6
Dec 22	3.78
Dec 22	4.39
Dec 22	4.23
Dec 22	4.53
Nov 22	4.47
Nov 22	4.59
Nov 22	4.43
Nov 22	3.11
Oct 22	3.11
Oct 22	3.41
Oct 22	3.48
Oct 22	3.66
Sep 22	3.57
Sep 22	3.92
Sep 22	4.87
Sep 22	5.11
Sep 22	4.95
Aug 22	5.57
Aug 22	6.41
Aug 22	6.11
Aug 22	7
Jul 22	6.23
Jul 22	6.46
Jul 22	6.24
Jul 22	6.06
Jul 22	5.31
Jun 22	5.37
Jun 22	5.33
Jun 22	6.28
Jun 22	5.26
May 22	5.44
May 22	5.04
May 22	4.66
May 22	4.85
Apr 22	5.16
Apr 22	6.58
Apr 22	8.51
Apr 22	9.07
Apr 22	9.96
Mar 22	10.13
Mar 22	11.5
Mar 22	11.37
Mar 22	8.08
Feb 22	9.18
Feb 22	9.98
Feb 22	11.69
Feb 22	12.23
Jan 22	12.44
Jan 22	13.73
Jan 22	15.02
Jan 22	16.95
Dec 21	18.77
Dec 21	20.49
Dec 21	21.13
Dec 21	18.88
Dec 21	18.13
Nov 21	20.12
Nov 21	21.35
Nov 21	23.06
Nov 21	25.31
Oct 21	32.22
Oct 21	32.22
Oct 21	35.71
Oct 21	36.82
Oct 21	37.45
Sep 21	42.37
Sep 21	44.44

Price to Book

SLDB Price to Book by year
Period	Price to Book
Sep 26	3.34
Sep 26	3.94
Aug 26	3.75
Aug 26	3.57
Aug 26	3.53
Aug 26	3.22
Jul 26	2.37
Jul 26	2.3
Jul 26	2.56
Jul 26	3.06
Jul 26	3.18
Jun 26	2.73
Jun 26	2.44
Jun 26	2.1
Jun 26	1.97
May 26	2.15
May 26	1.94
May 26	2.03
May 26	3.83
May 26	3.75
Apr 26	4.17
Apr 26	4.54
Apr 26	4.22
Apr 26	3.94
Mar 26	3.74
Mar 26	3.7
Mar 26	3.17
Mar 26	2.92
Feb 26	2.69
Feb 26	2.47
Feb 26	2.68
Feb 26	2.82
Jan 26	2.8
Jan 26	2.86
Jan 26	2.37
Jan 26	2.29
Jan 26	2.36
Dec 25	2.53
Dec 25	2.57
Dec 25	2.54
Dec 25	2.5
Nov 25	2.35
Nov 25	2.04
Nov 25	1.84
Nov 25	1.76
Oct 25	1.96
Oct 25	2.05
Oct 25	2.14
Oct 25	2.17
Oct 25	2.15
Sep 25	2.24
Sep 25	1.87
Sep 25	1.96
Sep 25	2
Aug 25	2
Aug 25	2.16
Aug 25	2.23
Aug 25	1.42
Aug 25	1.54
Jul 25	1.58
Jul 25	1.44
Jul 25	1.19
Jul 25	1.13
Jun 25	1.06
Jun 25	1.08
Jun 25	1.02
Jun 25	1.02
May 25	0.72
May 25	0.63
May 25	0.62
May 25	1.08
May 25	1.68
Apr 25	1.29
Apr 25	1
Apr 25	1.05
Apr 25	1.22
Mar 25	1.69
Mar 25	1.8
Mar 25	1.99
Mar 25	2.12
Feb 25	1.39
Feb 25	1.43
Feb 25	1
Feb 25	0.71
Jan 25	0.79
Jan 25	0.8
Jan 25	0.81
Jan 25	0.91
Jan 25	1.03
Dec 24	1.05
Dec 24	1.03
Dec 24	1.22
Dec 24	1.25
Nov 24	1.41
Nov 24	1.34
Nov 24	1.2
Nov 24	1.46
Nov 24	1.22
Oct 24	1.21
Oct 24	1.4

No video analysis for this stock yet. Request one from our team.

News: SLDB

seekingalpha.com · 10 Sep 2026

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

globenewswire.com · 2 Sep 2026

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare Conference Bo Cumbo, President and CEO, and Gabriel Books, M.D.

seekingalpha.com · 2 Jul 2026

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform with clinical validation momentum. SLDB's $380.7M cash position funds operations into 2028, supporting high-cost Phase 3 SGT-003 trials and multiple pipeline programs without near-term dilution risk. SGT-003's Phase 1/2 data show strong microdystrophin expression and safety, while additional programs in Friedreich's ataxia and CPVT expand addressable markets.